Heterotricyclic compounds for use as HCV inhibitors

Details Heterotricyclic compounds for use as HCV inhibitors Heterotricyclic compounds for use as HCV inhibitors

2005-06-03

2009-08-04

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S083000

Reexamination Certificate

active

07569580

ABSTRACT:
The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a mammal.

REFERENCES:
patent: 4000151 (1976-12-01), Hester, Jr.
patent: 4581455 (1986-04-01), Wright
patent: 2004/0048882 (2004-03-01), Angibaud et al.
patent: 2004/0082592 (2004-04-01), Mabire et al.
patent: 2005/0090521 (2005-04-01), Thota et al.
patent: 2007/0149520 (2007-06-01), Thota et al.
patent: 2206012 (1972-08-01), None
patent: 0 120 484 (1984-10-01), None
patent: 1162196 (2001-12-01), None
patent: 1 374 369 (1974-11-01), None
patent: WO95/26348 (1995-10-01), None
patent: WO97/48704 (1997-12-01), None
patent: WO2002/28837 (2002-04-01), None
patent: WO2003/007945 (2003-01-01), None
patent: WO2003/040112 (2003-05-01), None
patent: WO2003/064456 (2003-08-01), None
patent: WO2005/0307774 (2005-04-01), None
Yanborosova et al., Preparation and pharmacological activity of amides of 2-hydrazocinchoninic, 1,2,4-triazolo [4,3-a]-, and 1,2,3,4-tetrazolo[4,3-a]quinoline-9-carboxylic acids, Khimiko-Farmatsevticheskaya Zhurnal 30(3): 52-53 (1996).
Stn results, Document No.: 125:75750, Registry No.(s): 136354-35-6, 178533-22-7, 178533-23-8, 178533-24-9, 178533-25-0, 178533-26-1, and 178533-27-2.
Filer, C.N. et al., “Isoquinolines.8.Ethylene Oxide Mediated Conversion of Isoquinolines to Isoquinolones and Oxazolidines. Its Extension to Related Nitrogen Heterocycles”, J. Org. Chem., vol. 44, No. 2, 1979 pp. 285-287.
Van Nispen, Simon et al., “Use of Dilithio-Tosylmethyl Isocyanide in the Synthesis of Oxazoles and Imidazoles”, Tetrahedron Letters, vol. 21, pp. 3723-3726.
Tominaga, Yoshinori et al., “Polarized Ethylene. V. Synthesis of 1-Substituted Indolizine, Pyrazolo[1,5-a]pyridine, and Their Related Compounds Using Methoxyethylene Derivatives”, Journal of Heterocyclic Chemistry, vol. 27, No. 263, 1990, pp. 263-268.
Roberts, Edward M. et al., “A Synthesis of 5,6-Benzopyrrocoline”, Journal of Organic Chemistry, American Chemical Society, vol. 20, 1955, pp. 1443-1447.
Smith, R.M. et al., “Structure-Based Design of Hepatitis C Virus Inhibitors”, Journal of Viral Hepatitis, vol. 10, 2003, pp. 405-412.
Invitation to Pay Additional Fees, PCT International Application No. PCT/US2005/019499, Aug. 3, 2006.
Mukherjee et al., “Synthesis and Bioevaluation of Substituted Dihydropyridines for Pregnancy-Interceptive Activity in Hamsters” J. Med. Chem., 32(10):2297-2300 (1989).
Meth-Cohn et al., “A Versatile New Synthesis of Quinolines and Related Fused Pyridines,” Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry, 9:2509-2517 (1981).
McGaw, What it Means When an Examiner Says “Election of Species Requirement”, Smith & Hopen, Article ID: 37 (2005).
Database Beilstein XP002313584, Database accession No. Beilstein Registry No.: 13090-43-2, S-triazolo ′1, 5-alauinoline & Heterocycles vol. 31, No. 2, 1990, pp. 289-304.
Tetrahedron, vol. 54, 1998, pp. 3913-3918, XP002313579, compound 7.
Caplus Accession No. 1996: 464309.
Stadbauer, et al., “Study of the Thermal Behavior of Azidohetarenes with Differential Scanning Calorimetry”, Journal of Biochemical and Biophysical Methods, (2002), vol. 53, 89-99.
Caplus Accession No. 1994: 533294.
Caplus Accession No. 1993: 551632.
Caplus Accession No. 1990: 138965.
Caplus Accession No. 1986: 583403.
Caplus Accession No. 1986: 442681.
Search Report for PCT/US2004/031705 dated Feb. 2, 2005.
STN International Search Report, 39 pages.

Affiliated with

Also associated with

Rating

Heterotricyclic compounds for use as HCV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterotricyclic compounds for use as HCV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterotricyclic compounds for use as HCV inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131844